Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (390)	3/19/2004 10:22:54 AM
From: rkrw	Respond to of 523

I just wish the price were better. I'm sure they do too, but what can you do? This should make nrgn a lot more fun as an investment as they'll have the money to take greater risk and retain programs. They have a few undisclosed/unpartnered pre-clinical programs. There must be one or two in particular they felt were worth pursuing independently and taking this kind of equity hit for. Perhaps nrgn is considering branching out from neuro, such as into small molecules against cancer targets. nrgn is going to be a lot more interesting is for certain.